Close Menu

ORLANDO – Researchers at Ohio State University have developed a rapid single-molecule nanopore sequencing assay that can analyze blood samples from acute myeloid leukemia patients for clinically actionable and prognostic markers in a few hours.

The team, led by OSU's Esko Kautto and James Blachly, designed the test on Oxford Nanopore Technologies' MinIon sequencer, aiming for same-day analysis of AML patients' DNA so the detected genomic variants may be used to guide treatment or inform their prognosis.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Feb
05
Sponsored by
LGC

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.